Select your country or region to view content specific to your country.
Oct 27, 2021
- A true walk away ‘sample to answer’ molecular diagnostic system designed for high throughput testing, offering a time-efficient and seamless workflow for clinical laboratories
- Utilizes Seegene’s patented, cutting-edge high multiplex real-time PCR technologies to provide ‘Real’ Ct values of individual pathogens in a single channel.
- Incorporates Seegene’s broad menu of molecular diagnostics for syndromic testing, including detection of SARS-CoV-2 and variants.
South Korea’s leading molecular diagnostics (MDx) developer
Seegene Inc., (KQ 096530) is addressing the needs of small, mid-sized, and
large hospitals and COVID-19 laboratories with its fully automated
STARlet-AIOS: All-in-One System (AIOS). First unveiled at the 2021 AACC Annual
Scientific Meeting & Clinical Lab Expo in Atlanta, the modular system
supports a “hands-free” PCR workflow, automating everything from nucleic acid
extraction to the interpretation of results. This can help sites boost
their testing capacity while lessening the burden on laboratory and hospital staff.
“Seegene has played a critical role in the global response
to the COVID-19 pandemic, in large part because of our forward-looking
strategy. We moved fast from day one, rapidly developing a reliable assay for
the novel coronavirus and then pivoting to multiplexed tests that can detect
emerging SARS-CoV-2 variants,” said Dr. Jong-Yoon Chun, Seegene Founder
and CEO. “As we look ahead, the most pressing diagnostic need will be for
cost-effective and high throughput automated systems that can remove any remaining
testing bottlenecks. Our all-in-one system specifically addresses that need for
hospitals and laboratories of all sizes.”
More than 3.75 billion people worldwide have now received at least one dose of a COVID-19 vaccine. As daily case counts and fatalities decline, many countries are easing their restrictions and preparing to live with the virus. Doing so safely will require ongoing surveillance, with accurate PCR testing and rapid turnaround times.
The modular design of STARlet-AIOS: All-in-One System unites two standalone instruments–the STARlet IVD and the CFX96™ Dx real-time PCR System––with a custom-built robotic arm. This unique engineering allows customers to either purchase the full AIOS system or integrate existing Seegene instruments already in use. With its compact and intuitive design, the AIOS is accessible to small-to-medium sized hospitals and clinics, along with larger organizations.
Seegene’s current portfolio with an extensive test menu including GI, HPV, STI, respiratory assays as well as a suite of SARS-CoV-2 assays detecting a wide range of variants (namely, Alpha, Beta, Gamma, Delta, Epsilon, kappa, Lambda, Mu, etc.) can all be processed using the AIOS. The system will also be compatible with newly developed assays and Seegene’s MOBILE STATION, an innovative laboratory-on-wheels initiative that delivers mass testing capacity to communities that would otherwise lack the necessary infrastructure.
Meanwhile, the company plans to introduce
Allplex™ Respiratory Virus Master Assay, in late 2021, a single tube
syndromic assay that can differentiate between COVID-19 and other major
common respiratory pathogens, such as influenza, RSV, adenovirus,
parainfluenza, metapneumovirus, human rhinovirus. The introduction of the
new assay will help doctors treat cases more effectively, by differentiating
causative pathogens of COVID-19 and respiratory viruses for common flu, which
may surge in winter season.